"It seems like a money-saving exercise," she said. "If a patient dies, tough."
November 17, 2008 9:27 AM Subscribe
£35,000-a-year kidney cancer drugs too costly for NHS: Sutent offers to extend a kidney or GIST cancer patient's life by about 26 months, but the British NHS refuses to fund it, citing "marginal benefit at quite often an extreme cost."
This thread has been archived and is closed to new comments